When given orally, Firibastat (0.1-30 mg/kg; p.o.) crosses the gastrointestinal and blood-brain barriers, enters the brain, and generates two active molecules of EC33 which inhibit brain APA activity, blocking brain angiotensin III formation, and decrease blood pressure for several hours in hypertensive rats.
Animal Model: |
Normotensive and hypertensive DOCA-salt rats |
Dosage: |
0.1-30 mg/kg |
Administration: |
P.o. |
Result: |
Resulting in a dose-dependent decrease in mean arterial blood pressure (MABP).
|